Program
Continuing Medical Education
Jointly Provided by
Society for Birth Defects Research and
Prevention
2020 Virtual Annual Meeting
On Demand CME Modules Available through May 2021
Module 1: President’s Welcome, Josef Warkany Lecture, and
Robert L.
Brent Lecture—Teratogen Update from Dysmorphology to
Next‐Generation Phenotyping
Chairperson: Christine Perdan
Curran, Northern Kentucky University
(90 minutes, original air date
June 25, 2020)
Learning
Objectives
At the conclusion of this activity, participants will be
able to:
1. Identify typical dysmorphic findings seen in RASopathies.
2. Use a next‐generation phenotyping tool for digital
facial analysis.
Presentations and Speakers
·
POPs: A Plethora
of Developmental Effects, Linda
S. Birnbaum, Scientist Emeritus and Former Director, National Institute of
Environmental Health Sciences and National Toxicology Program
·
From
Dysmorphology to Next-Generation Phenotyping, Karen W. Gripp, A.I. duPont Hospital for Children/Nemours
Module 2: Gene Therapy: CRISPR/Cas9 Technology,
Breakthroughs, and Ethical Challenges Symposium
Chairpersons: Gloria D. Jahnke, National Institute of
Environmental Health Sciences and Evi Struble, US Food and Drug Administration
(120 minutes, original air date June 29, 2020)
Learning Objectives
At
the conclusion of this activity, participants will be able to:
1.
Summarize
the molecular basis
of CRISPR/Cas9 genome‐editing technique including off‐target effects
and other potential toxicities.
2.
Discuss its applications in the laboratory and whole organism
scale to understand pathophysiology of inheritable diseases such as NAD deficiency.
3.
Understand
preclinical considerations for human gene therapy products
involving genome editing
by CRISPR/Cas.
4.
Identify ethical concerns
around the use of genome
editing to alter somatic and germline cells and the potential
societal implications of such individual or inheritable changes.
Presentations and Speakers
· Introduction
to CRISPR‐Cas9 Gene Editing, Jennifer
Mason, Clemson University
· The
Use of CRISPR/Cas9 Technology to Study Congenital Malformations Caused by NAD
Deficiency, Paul R. Mark, Spectrum Health
Medical Group
· Gene
Therapy Products Using CRISPR/CAS9: Applications and Regulatory Considerations,
Shana D. Hardy, US Food and Drug Administration
· Ethical
and Governance Considerations of Germline Gene Editing, Eric T. Juengst, University of North Carolina, Chapel Hill
Module 3: Investigation of a Potential Outbreak of Birth Defects Symposium
Chairpersons: Sonja A. Rasmussen,
University of Florida and Cheryl S. Broussard, Centers for Disease Control and
Prevention
(120 minutes, original air date June 29, 2020)
Learning
Objectives
At the conclusion of this activity, participants will be
able to:
1. Describe the ten steps in a field investigation when
concern for an increased rate of birth defects is raised.
2. Describe the critical role played by birth defects
surveillance systems to address a possible increased rate of birth defects.
3. Identify ways to develop interventions to respond to an
increase in the rate of birth defects.
4. Discuss key principles to guide communications with the
public when responding to an increased rate of
birth defects.
Presentations and Speakers
·
Ten Steps to a Field
Investigation of an Increased Rate of Birth Defects, Sonja A. Rasmussen, University of Florida
·
Using Birth Defects Surveillance
to Address a Possible Increased Rate of Birth Defects, Peter H. Langlois, Texas Department of State Health Services
·
Developing Interventions in
Response to an Increase in Birth Defects, Cheryl
S. Broussard, Centers for Disease Control and Prevention
·
Communicating with the Public
during a Public Health Emergency Response, Glen
J. Nowak, University of Georgia
Module 4: Keynote Lecture and
Agnish Fellowship Lecture
Chairperson: Elise M. Lewis,
Charles River
(75 minutes, original air date
June 30, 2020)
Learning Objectives
At the
conclusion of this activity, participants will be able to:
1.
Recognize the
benefits and limitations of maternal plasma cell free DNA as a screen for fetal
aneuploidy.
2.
Describing
underlying reasons for "false positive" cell‐free DNA results
and what we have learned from them.
Presentations and Speakers
·
Prenatal Genomic Medicine:
Transforming Obstetric Practice and Delivering New Biological Insights, Diana W. Bianchi, Eunice Kennedy Shriver
National Institute of Child Health and Human Development
·
Educating Future
Birth Defects Researchers: Opportunities in the Era of Personalized Medicine,
Systems Biology, and CRISPER Technologies, Elaine M. Faustman, University of
Washington
Module 5: Assessing and Modeling Perinatal and Postnatal Exposures to Environmental Chemicals in Support of Human Health Risk Assessment Symposium
Chairpersons: Laura Carlson, US
Environmental Protection Agency and Geniece Lehmann, US Environmental
Protection Agency
(120 minutes, original air date
June 30, 2020)
Learning
Objectives
At the conclusion of this activity, participants will be
able to:
1.
Summarize current approaches that
can be used in modeling gestational and lactational exposures to environmental
chemicals.
2.
Understand environmental exposures important
to infants and children and Identify key uncertainties and data gaps in
our understanding of children’s exposures to chemicals from breast milk,
formula, and nondietary sources.
3.
Describe the unique metabolic,
physiological, and behavioral characteristics of pregnancy and early
development and how they are accounted for in different exposure assessments
and pharmacokinetic modeling.
4.
Understand methods that may be used to develop
risk assessments that can better
protect children’s health.
Presentations and Speakers
· Environmental
Chemicals in Breast Milk and Formula: Exposure and Risk Assessment
Implications, Judy S. LaKind, LaKind
Associates
· Level
of Detail for Pharmacokinetic Modeling During Development: Time or Tissues, But
Not Both, Paul M. Schlosser, US Environmental
Protection Agency
· Pharmacokinetic
Modeling as a Tool to Bridge In Vitro, In Vivo, and Epidemiological Data in
Risk Assessment of Developmental Exposures, Marc‐Andre
Verner, University of Montréal
· Children’s
Nondietary Exposures to Environmental Chemicals, Paloma I. Beamer, University of Arizona
· A
Review of Factors Influencing Children’s Exposure Assessment, Geniece Lehmann, US Environmental Protection
Agency
Module 6: Opioid Use in
Pregnancy: Translational Perspectives Symposium
Chairpersons: Christina D.
Chambers, University of California–San Diego and Rina Eiden, Pennsylvania
State University
(120 minutes, original air date
June 30, 2020)
Learning Objectives
At the conclusion of this activity,
participants will be able to:
1. Describe known risks for adverse birth and
long‐term child health outcomes with prenatal opioid exposure.
2. Identify epigenetic mechanisms that may be involved in
susceptibility and severity of neonatal opioid withdrawal syndrome (NOWS).
3. Discuss successful interventions and strategies for
treatment of infants with NOWS.
4. Describe one successful parenting intervention with
m‐health delivery for parents/caregivers of infants or toddlers who
experienced NOWS.
Presentations and Speakers
· Outcomes among Children of Opiate Using Mothers, Elisabeth Conradt, University of Utah
·
A Translational Model of
Gestational Buprenorphine Exposure: Effects on the Dam and the Offspring, Susanne Brummelte, Wayne State University
·
Prenatal Exposure to Opioids and
Other Substances: What Do We Know about Later Development Outcomes?, Hendrée Jones, UNC Department of Obstetrics
& Gynecology
· Modifying an Evidence‐Based Home Visiting
Intervention for Mothers with Opioid Dependence, Mary Dozier, University of Delaware
Module 7: Pregnancy, Environment,
and Child Health: A Focus on Obesity and Metabolic Disorders
Chairpersons: Suzanne E. Fenton,
National Institute of Environmental Health Sciences and Jerrold J. Heindel,
Commonweal
(120 minutes,
original air date July 1, 2020)
Learning Objectives
At the conclusion of this activity,
participants will be able to:
1. Understand the incidence and breadth of obesity in the
U.S. and around the world.
2. Describe the health‐related costs that obesity is
causing in the U.S.
3. Identify many environmental chemicals that may be contributing to the obesity
epidemic, and their potential modes
of action.
4. Describe the many ways that obesity is contributing to related health problems in susceptible subpopulations and the importance of
reducing obesity in these people.
Presentations and Speakers
· Endocrinological and Environmental Control of Obesity, Jerrold J. Heindel, Commonweal
·
Environmental Influences on the
Childhood Obesity Epidemic, Leonardo
Trasande, NYU School of Medicine
· Effects of Developmental Exposure to Genx on Mouse
Offspring: Pubertal and Metabolic Targets, Suzanne
E. Fenton, National Institute of Environmental Health Sciences
·
How Does Prenatal Obesogen
Exposure Lead to a Transgenerational Predisposition to Obesity?, Bruce Blumberg, University of California,
Irvine
·
The Role of Maternal Obesity and
Pregnancy Weight Gain Patterns in Pregnancy and Birth, and Longer‐Term
Health Outcomes, Elizabeth Widen,
University of Texas at Austin
Module 8: Single‐Cell
Revolution: Embryogenesis at High‐Resolution Symposium
Chairpersons: Thomas B. Knudsen, National Center for
Computational Toxicology, US EPA and Elaine M. Faustman, University of
Washington
(120 minutes, original air date July 2, 2020)
Learning
Objectives
At the
conclusion of this activity, participants will be able to:
1. Describe new methods of single cell transcriptomic
analysis.
2.
Identify how single cell
transcriptomic profiles can improve our understanding of normal development.
3. Understand how single cell transcriptomics can be used to characterize developmental disease progression and define precision therapy.
4.
Characterize how single cell transciptomics can facilitate our identification and evaluation of cell specific
targets of developmental and reproductive toxicants.
5.
Identify remaining challenges in
application of these new technologies.
Presentations and Speakers
· Teratogenesis at the Single‐Cell Level:
Opportunities and Challenges, Thomas B.
Knudsen, National Center for Computational Toxicology, US EPA
·
Development and Disease at Single
Cell Resolution Development and Disease at Single Cell Resolution, Malte Spielmann, Max Planck Institute for
Molecular Genetics
·
What scRNAseq Is Now Telling Us
about Embryology, Sean Megason, Harvard
Medical School
·
How Single‐Cell Profiling
Data Can Be Applied to Improve Children’s Health, Elaine M. Faustman, University of Washington
| Target Audience | Physicians and Advance Practice Professionals involved or interested in the causes and prevention of birth defects and developmental disorders and the research related to such. |
| Competencies to be addressed | Practice Based Learning and Improvement |
| Activity Director | Sonja A. Rasmussen, MD, MS |
| Registration | Access to the On Demand CME Modules is included in the registration fee for the Society for Birth Defects Research and Prevention 60th Annual Meeting. Physicians, Physicians Assistants, and Nurse Practitioners may register at the following link: Registration Link Please select Full Virtual Meeting Registration or One-Day Registration (select the original date of the module(s) you wish to view) and use Discount Code founded1960 to get 30% off the registration fee shown. |
Accreditation  |
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and the Society for Birth Defects Research and Prevention. USF Health is accredited by the ACCME to provide continuing medical education for physicians |
| Disclosures | USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation(s). Detailed disclosure will be made at the beginning of each presentation in the modules. |
| How to Claim Credit | Instructions on how to claim credit are in the Handout section of each CME Module.. You must claim credit for each individual CME Module. Each Handout includes a code unique to that CME Module. Please make sure to view the CME Module(s) in entirety. Once you have followed the instructions to claim credit, please send an email to BDRP@birthdefectsresearch.org indicating which CME Module(s) you are claiming credit for and request that verification be sent to USF Health that you viewed the CME Module(s) in entirety. |
| Commercial Support | There is no commercial support for this activity. |
| Disclaimer | The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. |
| Equal Opportunity and ADA | USF is an Equal Opportunity / Affirmative Action / Equal Access Institution. |
| CME Questions / Concerns | Contact Charmagne Branch-Price, Education Coordinator, Office of Continuing Professional Development USF Health, cbranch@usf.edu |